AnteMEL

350.00

AnteMEL is a genetic test that determines the risk of developing melanoma.

Melanoma is a malignant skin cancer, which is constantly on the rise and is affecting people of all ages. In the absence of population-based screening programs for melanoma in Europe, it is important to find new prevention measures. For this we have developed the AnteMEL test. AnteMEL aims to identify people at increased risk for cancer and reduce the risk of premature mortality due to melanoma.

AnteMEL is a registered in vitro diagnostic device (IVD medical device) and it has been developed by the healthcare service provider Antegenes (License: L04685).

What does AnteMEL test include?

  • Analyzes of 28 genetic variants associated with melanoma;
  • Individual polygenic risk score for melanoma;
  • The individual risk of melanoma compared to the rest of the population;
  • Likelihood to get melanoma in 10 years and risk assessment compared to a person with average genetic risk;
  • Interpretation of the test results with clinical recommendations;
  • Genetic counseling.

Who can benefit from AnteMEL test?

AnteMEL test is recommended for:

  • Men and women between the ages of 18-70 of European origin (Note: Genetic risk studies used by AnteMEL have been conducted in populations of European descent).

The AnteMEL test is not recommended:

  • If the patient has a high-risk mutation in a single gene predisposed to melanoma (BRCA2, CDKN2A, CDK4, TP53, PTEN etc.).

What is needed for AnteMEL testing?

AnteMEL testing requires the patient’s DNA, which is collected and isolated from the buccal swab sample (cells inside the cheek are collected with a special cotton swab).

How long does it take to get AnteMEL test results?

Test results are available within 6 weeks from the sample being received by Antegenes.

AnteMEL Test Limitations

  • AnteMEL test is not used to diagnose melanoma.
  • AnteMEL test is not validated for use by individuals of non-European descent.
  • An elevated risk estimated by the AnteMEL test does not mean that the patient will develop melanoma during their lifetime. Also, a moderate or lower risk does not mean that the patient will not develop the disease.
  • AnteMEL test is patient-specific and does not assess the risk of the patient’s family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children.
  • AnteMEL test does not analyze rare pathogenic mutations in genes that significantly increase the risk of melanoma, such as CDKN2A, MC1R, CDK4, TP53, PTEN, BAP1, POT1, ACD, PARK2, TERF2IP, TERT, BRCA1, BRCA2, RB1.
  • The AnteMEL test is based on the most up-to-date scientific data, which may, however, be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations based on test results.
  • Different polygenic risk scores predicting risks of the same trait may give different estimates of the individual’s risks due to differences in the genetic variants included in the models and their weights.
  • The results of this test should be applied in context with other relevant clinical data. In addition to the possible genetic predisposition, other risk factors also influence the risk of skin melanoma.

CE

AnteMEL